| CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity BD Choi, X Yu, AP Castano, AA Bouffard, A Schmidts, RC Larson, ... Nature biotechnology 37 (9), 1049-1058, 2019 | 405 | 2019 |
| EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss JH Sampson, BD Choi, L Sanchez-Perez, CM Suryadevara, DJ Snyder, ... Clinical Cancer Research 20 (4), 972-984, 2014 | 330 | 2014 |
| CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma BD Choi, X Yu, AP Castano, H Darr, DB Henderson, AA Bouffard, ... Journal for immunotherapy of cancer 7, 1-8, 2019 | 241 | 2019 |
| Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma MJ Frigault, J Dietrich, M Martinez-Lage, M Leick, BD Choi, Z DeFilipp, ... Blood, The Journal of the American Society of Hematology 134 (11), 860-866, 2019 | 212 | 2019 |
| Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma BD Choi, CT Kuan, M Cai, GE Archer, DA Mitchell, PC Gedeon, ... Proceedings of the National Academy of Sciences 110 (1), 270-275, 2013 | 169 | 2013 |
| EGFRvIII‐targeted vaccination therapy of malignant glioma BD Choi, GE Archer, DA Mitchell, AB Heimberger, RE McLendon, ... Brain pathology 19 (4), 713-723, 2009 | 168 | 2009 |
| A versatile platform for generating engineered extracellular vesicles with defined therapeutic properties K Dooley, RE McConnell, K Xu, ND Lewis, S Haupt, MR Youniss, S Martin, ... Molecular Therapy 29 (5), 1729-1743, 2021 | 167 | 2021 |
| EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma H Miao, BD Choi, CM Suryadevara, L Sanchez-Perez, S Yang, G De Leon, ... PloS one 9 (4), e94281, 2014 | 148 | 2014 |
| Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma BD Choi, CM Suryadevara, PC Gedeon, JE Herndon II, L Sanchez-Perez, ... Journal of clinical neuroscience 21 (1), 189-190, 2014 | 124 | 2014 |
| Chimeric antigen receptor costimulation domains modulate human regulatory T cell function AC Boroughs, RC Larson, BD Choi, AA Bouffard, LS Riley, E Schiferle, ... JCI insight 4 (8), 2019 | 107 | 2019 |
| Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment Y Kfoury, N Baryawno, N Severe, S Mei, K Gustafsson, T Hirz, T Brouse, ... Cancer cell 39 (11), 1464-1478. e8, 2021 | 106 | 2021 |
| Bispecific antibodies engage T cells for antitumor immunotherapy BD Choi, M Cai, DD Bigner, AI Mehta, CT Kuan, JH Sampson Expert opinion on biological therapy 11 (7), 843-853, 2011 | 105 | 2011 |
| Factors influencing fellowship selection, career trajectory, and academic productivity among plastic surgeons MR DeLong, DB Hughes, VJ Tandon, BD Choi, MR Zenn Plastic and reconstructive surgery 133 (3), 730-736, 2014 | 103 | 2014 |
| Immunotherapy for glioblastoma: adoptive T-cell strategies BD Choi, MV Maus, CH June, JH Sampson Clinical Cancer Research 25 (7), 2042-2048, 2019 | 97 | 2019 |
| Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma A Schmidts, M Ormhøj, BD Choi, AO Taylor, AA Bouffard, I Scarfò, ... Blood Advances 3 (21), 3248-3260, 2019 | 90 | 2019 |
| Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma CM Suryadevara, R Desai, ML Abel, KA Riccione, KA Batich, SH Shen, ... Oncoimmunology 7 (6), e1434464, 2018 | 88 | 2018 |
| Are BiTEs the “missing link” in cancer therapy? CM Suryadevara, PC Gedeon, L Sanchez-Perez, T Verla, ... Oncoimmunology 4 (6), e1008339, 2015 | 82 | 2015 |
| Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody BD Choi, PC Gedeon, JE Herndon, GE Archer, EA Reap, ... Cancer immunology research 1 (3), 163-167, 2013 | 77 | 2013 |
| Myeloablative Temozolomide Enhances CD8+ T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice LA Sanchez-Perez, BD Choi, GE Archer, X Cui, C Flores, LA Johnson, ... PloS one 8 (3), e59082, 2013 | 77 | 2013 |
| Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial MJ Frigault, J Dietrich, K Gallagher, M Roschewski, JT Jordan, D Forst, ... Blood, The Journal of the American Society of Hematology 139 (15), 2306-2315, 2022 | 75 | 2022 |
John H. Sampson, M.D., Ph.D., M.H.Sc...Wilkins Distinguished Professor and Chief of NeurosurgeryVerified email at duke.edu
